Table 1 Baseline characteristics of patients
|  | KIT mutated treated with VEN/HMA (Cohort A, n = 16) | KIT wild-type treated with VEN/HMA (Cohort B, n = 141) | p | KIT mutated treated with IC (Cohort C, n = 69) | p |
|---|---|---|---|---|---|
Age |  |  | 0.165 |  |  < 0.001 |
 < 65 | 9 (56.3%) | 54 (38.3%) |  | 65 (94.2%) |  |
 ≥ 65 | 7 (43.8%) | 87 (61.7%) |  | 4 (5.8%) |  |
Sex | Â | Â | 0.936 | Â | 0.365 |
 Male | 8 (50.0%) | 69 (48.9%) |  | 43 (37.7%) |  |
 Female | 8 (50.0%) | 72 (51.1%) |  | 26 (62.3%) |  |
ECOG PS | Â | Â | 0.015 | Â | 0.320 |
 < 2 | 10 (62.5% | 45 (31.9%) |  | 54 (78.3%) |  |
 ≥ 2 | 6 (37.5%) | 96 (68.1%) |  | 15 (21.7%) |  |
Type of HMA | Â | Â | 0.391 | Â | / |
 Azacitidine | 16 (100%) | 14 (9.9%) |  | / |  |
 Decitabine | 0 (0%) | 127 (90.1%) |  | / |  |
Bone marrow blast | Â | Â | 0.986 | Â | 0.576 |
 < 50% | 7 (43.8%) | 62 (44.0%) |  | 25 (36.2%) |  |
 ≥ 50% | 9 (56.3%) | 79 (56.0%) |  | 44 (63.8%) |  |
FAB-M5 | 6 (37.5%) | 56 (39.7%) | 0.864 | 23 (33.3%) | 0.751 |
 ELN 2022 risk group |  |  |  < 0.001 |  | 0.489 |
  Favorable | 14 (87.5%) | 38 (27.0%) |  | 62 (89.9%) |  |
  Intermediate | 0 (0%) | 25 (17.7%) |  | 3 (4.3%) |  |
  Adverse | 2 (12.5%) | 78 (55.3%) |  | 4 (5.8%) |  |
CBF-AML | 14 (87.5%) | 10 (7.1%) |  < 0.001 | 64 (92.8%) | 0.854 |
 FLT3-ITD/TKD mutation | 4 (25.0%) | 31 (22.0%) | 1.000 | 11 (15.9%) | 0.622 |
TP53 mutation | 0 (0.0%) | 20 (14.2%) | 0.226 | 0 (0.0%) | / |
 Allo-HSCT | 4 (25.0%) | 18 (12.8%) | 0.339 | 28 (40.6%) | 0.247 |